When Leftover Disease Turns Up in Several Places at Once: Why Treatment Shifts From Local to Systemic, and What to Sort Out While Waiting for the PET-CT

Some people finish a course of chemotherapy knowing that the disease shrank but never fully disappeared, and then live for a while on follow-up scans alone. When one of those scans shows lesions in several places, the language in the clinic changes abruptly: surgery is unlikely, let us restart chemotherapy, radiotherapy is worth considering, let us get a PET-CT first and take it to the multidisciplinary team. These four sentences are not contradictory. Each answers a different question, but they can sound like one blur the first time you hear them.

First, leftover disease and recurrence are not the same phrase. Treatment response is usually recorded as complete response, partial response, stable disease, or progression. If lesions shrank but remained, there was never a complete response, so lesions growing or multiplying now is closer to progression of disease that was already there than to something new coming back. Which label appears in your record affects how the next treatment is chosen and how survival statistics should be read, so it is worth asking your team to say plainly which one applies.

Surgery often drops off the list because of number and distribution rather than fitness. Local treatments such as resection or radiofrequency ablation matter most when everything visible can be removed. If lesions are scattered across more than one organ, taking out one or two leaves the rest behind and can cost weeks of recovery for little gain. That is why multifocal disease shifts the centre of gravity toward systemic therapy: chemotherapy, targeted therapy, or immunotherapy. This is a change of order, not an abandonment of treatment. If systemic therapy controls the disease well and only a few spots remain, local treatment sometimes comes back onto the table.

The single word radiotherapy also splits at least three ways by purpose. One is curative-intent treatment aimed at eradicating disease. One is focused consolidation of a small number of lesions, such as stereotactic body radiotherapy (SBRT). One is palliative radiotherapy given to reduce pain, bleeding, or pressure. The number of sessions, the side-effect burden, and the expected outcome differ across all three. So the first question to ask is not how many weeks, but what the intent is.

A PET-CT is usually done first because it shows metabolic activity as well as size and surveys the whole body at once for restaging. It does not answer everything. Inflammation, infection, and recent procedure sites can light up as false positives; very small or metabolically quiet lesions can be missed; and organs that normally consume a lot of glucose, such as the brain, may need a separate MRI. The report becomes a direction only when it is read alongside prior CT scans, pathology, and blood tests.

Before the multidisciplinary meeting, sorting a few things in advance saves time. One, whether the goal of this round is cure or long-term control and symptom relief, since the same drug can be dosed, timed, and stopped differently depending on that goal. Two, the names and total cycles of every chemotherapy drug received so far, plus lingering side effects such as peripheral neuropathy, hearing change, or reduced heart function. Three, which areas have already been irradiated and how widely, because that determines whether the same site can be treated again. Four, whether a repeat biopsy or genomic and biomarker testing is planned, since tumour biology can change over time and results can change drug choice. Five, current weight trend, other medical conditions, and all medications. Six, whether any clinical trial is an option. Seven, fixed points in real life such as family events or work, which can genuinely influence the start date. Finally, write down three questions and bring the paper with you.

The days spent waiting for results are easier to hold if they are filled with notes: dated symptoms, weight, how much you actually ate, and where and how strongly it hurts. But new shortness of breath, weakness on one side, slurred speech, severe headache, pain that will not settle, fever at or above 38C, a sharp drop in urine output, or sudden swelling should not wait for the appointment. Contact the treating team or seek emergency care.

Hearing about further treatment just as hair has grown back, or setting aside a job or a family occasion again, is not solved by information. That weight also affects eating, sleeping, and the energy needed to keep appointments. Psycho-oncology referral, hospital social work, and survivorship support programmes are part of the plan rather than an optional extra, and asking earlier tends to work better than asking late.

This article is general information and does not replace individual diagnosis or treatment. Testing and treatment decisions differ from person to person, so please discuss your own situation with your medical team.